CervoMed CRVO 深 滬
交易中 09-24 10:24:01 美东时间
2.485
-0.025
-1.00%
華盛通- 最 高2.4999
- 今 開2.46
- 成交量 8858股
- 最 低 2.46
- 昨 收 2.51
- 總市值 3757.10万
- 52周最高 10.00
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 2.13
- 委 比 78.04%
- 總股本 1511.91万
- 歷史最高 17437.50
- 量 比 0.57
- 振 幅 1.59%
- 歷史最低 1.80
- 每 手 1
- 風險率 2.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CervoMed Inc. announced that its management will participate in the 5th Annual ROTH Healthcare Opportunities Conference in New York on September 29, 2026. The panel discussion titled "Frontiers in Neuroscience" will take place from 10:00 AM to 10:50 AM ET. CervoMed, a clinical-stage company developing treatments for age-related brain disorders, highlighted its lead drug candidate, neflamapimod, which targets neuroinflammation and neurodegeneratio...
09-22 11:30
CervoMed To Present Neflamapimod, Oral, Small Molecule, Drug Candidate Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, At ISFTD Annual Meeting
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union BOSTON, ...
09-10 19:33
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70) per share from the same period last year.
08-10 19:33
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
CervoMed's neflamapimod granted Innovation Passport for UK's ILAP program to accelerate development for DLB, a common dementia with limited treatment options. The program offers coordinated guidance from UK regulators and NHS to expedite patient access. Neflamapimod targets neuroinflammation and has shown promise in early trials.
08-04 09:15
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
CervoMed ( ($CRVO) ) has issued an update. On July 9, 2026, CervoMed Inc., a cl...
07-10 04:29
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
CervoMed Inc. will present five studies on neflamapimod, its oral drug candidate for dementia with Lewy bodies (DLB), at the AAIC meeting in London. The studies highlight neflamapimod's potential to slow DLB progression, reduce biomarkers of neurodegeneration, and improve basal forebrain atrophy. Neflamapimod, a p38α kinase inhibitor, has shown promising results in Phase 2 trials, including improved cognitive and functional outcomes. CervoMed is ...
07-06 11:30
CervoMed Raises $10 Million in Direct Offering
CervoMed ( ($CRVO) ) just unveiled an update. On June 22, 2026, CervoMed Inc. c...
06-23 04:30
CervoMed Receives U.S. Patent For Its Neflamapimod Drug Candidate For The Treatment Of Dementia With Lewy Bodies
CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecti...
06-18 19:07
